Kennedy Capital Management LLC Raises Holdings in Enovis Co. (NYSE:ENOV)

Kennedy Capital Management LLC boosted its stake in shares of Enovis Co. (NYSE:ENOV - Free Report) by 5.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 158,557 shares of the company's stock after acquiring an additional 8,743 shares during the quarter. Kennedy Capital Management LLC owned about 0.28% of Enovis worth $6,957,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Aster Capital Management DIFC Ltd acquired a new stake in shares of Enovis during the fourth quarter worth $29,000. Quadrant Capital Group LLC raised its position in Enovis by 53.0% during the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock valued at $30,000 after acquiring an additional 239 shares in the last quarter. UMB Bank n.a. lifted its stake in shares of Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after buying an additional 437 shares during the last quarter. Pinnacle Bancorp Inc. lifted its stake in shares of Enovis by 54.5% in the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock valued at $37,000 after buying an additional 300 shares during the period. Finally, FMR LLC raised its position in Enovis by 20.5% in the third quarter. FMR LLC now owns 2,840 shares of the company's stock worth $122,000 after purchasing an additional 484 shares in the last quarter. 98.45% of the stock is owned by hedge funds and other institutional investors.

Enovis Stock Up 2.0 %

Shares of NYSE ENOV traded up $0.62 during mid-day trading on Thursday, reaching $31.78. 238,515 shares of the company's stock traded hands, compared to its average volume of 737,361. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The business has a 50-day simple moving average of $38.03 and a 200 day simple moving average of $42.31. Enovis Co. has a 1-year low of $29.32 and a 1-year high of $57.08. The stock has a market cap of $1.81 billion, a P/E ratio of -14.49 and a beta of 1.86.

Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.92 by $0.06. The company had revenue of $560.98 million for the quarter, compared to the consensus estimate of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. On average, analysts expect that Enovis Co. will post 2.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reaffirmed a "buy" rating and issued a $64.00 target price on shares of Enovis in a research note on Wednesday, April 9th.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.